Recent network meta-analyses identified the relative outcomes of various vitiligo monotherapies on vitiligo at 6 months.

Lopez said the new cream, Opzelura, that came out two years ago has changed that. “About two-thirds of patients are seeing at least 75% improvement in the vitiligo on the face, and that’s just ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...

Incyte has made further progress with its ruxolitinib cream, notching up a phase 3 trial showing it can re-pigment skin in vitiligo ahead of a key FDA decision in atopic dermatitis.

Lisa: I follow a vitiligo management plan developed with my dermatologist where I use Opzelura ® (ruxolitinib) cream 1.5%. I ...

Intrinsic alterations in the skin of patients with vitiligo include a thicker epidermis with a reduced number of basal melanocytes and the presence of degenerated keratinocytes with swollen ...

Results in vitiligo came from the TRuE-V1 and TRuE-V2 studies, which showed that around 30% of patients treated with ruxolitinib cream twice daily achieved 75% or more improvement from baseline in ...

non-segmental vitiligo with genital involvement, hidradenitis suppurativa, lichen planus, and lichen sclerosus. Two Phase III trials, TRuE-PN1 and TRuE-PN2, assessing ruxolitinib cream for prurigo ...